CA2532078A1 - Naphthylene derivatives as cytochrome p450 inhibitors - Google Patents

Naphthylene derivatives as cytochrome p450 inhibitors Download PDF

Info

Publication number
CA2532078A1
CA2532078A1 CA002532078A CA2532078A CA2532078A1 CA 2532078 A1 CA2532078 A1 CA 2532078A1 CA 002532078 A CA002532078 A CA 002532078A CA 2532078 A CA2532078 A CA 2532078A CA 2532078 A1 CA2532078 A1 CA 2532078A1
Authority
CA
Canada
Prior art keywords
10alkyl
10alkynyl
10alkenyl
cycloc3
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002532078A
Other languages
English (en)
French (fr)
Inventor
Vanessa Smith
Anthony Nigro
Mark Mulvihill
Cara Cesario
Patricia Anne Beck
Arlindo Lucas Castelhano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OSI Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2532078A1 publication Critical patent/CA2532078A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002532078A 2003-07-10 2004-07-12 Naphthylene derivatives as cytochrome p450 inhibitors Abandoned CA2532078A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10
US60/486,382 2003-07-10
PCT/US2004/022282 WO2005007631A1 (en) 2003-07-10 2004-07-12 Naphthylene derivatives as cytochrome p450 inhibitors

Publications (1)

Publication Number Publication Date
CA2532078A1 true CA2532078A1 (en) 2005-01-27

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002532078A Abandoned CA2532078A1 (en) 2003-07-10 2004-07-12 Naphthylene derivatives as cytochrome p450 inhibitors

Country Status (15)

Country Link
EP (1) EP1654236A1 (is)
JP (1) JP4832295B2 (is)
KR (1) KR20060052799A (is)
CN (1) CN1819996B (is)
AU (1) AU2004257257B2 (is)
BR (1) BRPI0412424A (is)
CA (1) CA2532078A1 (is)
IL (1) IL172812A0 (is)
IS (1) IS8223A (is)
MX (1) MXPA06000401A (is)
NO (1) NO20060114L (is)
RU (1) RU2363696C2 (is)
SG (1) SG144941A1 (is)
UA (1) UA87822C2 (is)
WO (1) WO2005007631A1 (is)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058301A1 (en) * 2003-12-17 2005-06-30 Allergan, Inc. Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
WO2011153192A2 (en) 2010-06-01 2011-12-08 Angion Biomedica Corp. Cytochrome p450 inhibitors and uses thereof
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
KR20180039185A (ko) * 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
CN103328452A (zh) * 2010-12-13 2013-09-25 威尔金制药有限公司 金属酶抑制剂化合物
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
WO2014015137A2 (en) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
US9988374B2 (en) 2014-08-11 2018-06-05 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
CN104523967B (zh) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为cyp酶抑制剂的应用
JP2018501279A (ja) 2014-12-31 2018-01-18 アンギオン バイオメディカ コーポレイション 疾患を治療するための方法及び薬剤
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
KR102628073B1 (ko) 2017-01-10 2024-01-22 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로사이클 유도체
UY37556A (es) 2017-01-10 2018-07-31 Bayer Ag Derivados heterocíclicos como pesticidas

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (is) * 1960-05-04
NL131915C (is) * 1966-07-27
DE3508903A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3628545A1 (de) * 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
WO1994008973A1 (en) * 1992-10-21 1994-04-28 Sankyo Company, Limited Azole compound
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
CA2328973A1 (en) * 1998-04-23 1999-10-28 Akio Ojida Naphthalene derivatives, their production and use
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類

Also Published As

Publication number Publication date
AU2004257257B2 (en) 2011-05-12
IS8223A (is) 2006-01-10
UA87822C2 (ru) 2009-08-25
RU2006103996A (ru) 2006-07-10
AU2004257257A1 (en) 2005-01-27
NO20060114L (no) 2006-02-09
SG144941A1 (en) 2008-08-28
BRPI0412424A (pt) 2006-09-05
CN1819996B (zh) 2010-10-27
RU2363696C2 (ru) 2009-08-10
JP4832295B2 (ja) 2011-12-07
EP1654236A1 (en) 2006-05-10
JP2007523866A (ja) 2007-08-23
CN1819996A (zh) 2006-08-16
WO2005007631A1 (en) 2005-01-27
KR20060052799A (ko) 2006-05-19
MXPA06000401A (es) 2006-03-17
IL172812A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
CA2532078A1 (en) Naphthylene derivatives as cytochrome p450 inhibitors
US7994204B2 (en) Binding inhibitor of sphingosine-1-phosphate
AU2012328034B2 (en) (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
EP2368887B1 (en) 1, 2, 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
US7662844B2 (en) Naphthylene derivatives as cytochrome P450 inhibitors
AU2008247102A1 (en) 2 -pyridine carboxamide derivatives as sodium channel modulators
EP1442034A1 (fr) Derives de benzimidazoles et leur utilisation comme inhibiteurs de proteine kinase kdr
WO2004022523A2 (en) 1, 3-diamino-2-hydroxypropane prodrug derivatives
FR2542315A1 (fr) Nouveaux composes azoliques, leur preparation et leur utilisation comme antifongiques et fongicides
CA2126972C (en) Styrene derivative and salts thereof
AU758246B2 (en) N,N-substituted cyclic amine derivatives
CA2893239A1 (en) Substituted triazole and imidazole compounds
JP3415865B2 (ja) 光学活性アゾール化合物およびその用途
JP2021102645A (ja) メプリンアルファ及びベータの新規な阻害剤
WO1996031491A1 (fr) Agent antifongique de triazole
CZ72095A3 (en) Benzenealkanoic acids as such and for use in medicine, process of their preparation and their use for the preparation of medicaments and pharmaceutical preparations based thereon
WO2008119772A1 (en) Amide derivatives as inhibitors of aspartyl proteases
KR20030025931A (ko) 2-아미노티아졸린 유도체 및 ｎｏ-신타제 억제제로서의이의 용도
AU2017224343A1 (en) Novel pyrrolidine derivatives
US7288541B2 (en) Propylcarbamate derivatives as inhibitors of serine and cysteine proteases
WO1998033778A1 (en) Triazole derivatives
OA16888A (en) (4-phenylimidazol-2-YL) ethylamine derivatives useful as sodium channel modulators
JPH07291965A (ja) 新規なピロリジン誘導体

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued